Literature DB >> 11380326

Involvement of cyclooxygenase-2 in hyperplastic gastritis induced by Helicobacter pylori infection in C57BL/6 mice.

F Xiao1, T Furuta, M Takashima, N Shirai, H Hanai.   

Abstract

BACKGROUND AND AIMS: The hyperplastic changes observed in Helicobacter pylori-associated gastritis have been considered to increase the risk of gastric cancer. The aim of this study was to determine whether cyclooxygenase-2 is involved in the hyperplastic changes in mice infected with H. pylori.
METHODS: Seven-week-old, male C57BL/6 mice (n=40) were inoculated with the Sydney strain of H. pylori. Control mice (n=40) were treated with vehicle only. Half of the infected and control mice were fed an experimental diet containing etodolac (10 mg/kg/day) from 1 week after inoculation until the end of the experiment. The thickness of gastric pits, COX-2 mRNA and protein levels, and prostaglandin E2 (PGE2) levels in the gastric mucosa were determined before and 12, and 24 weeks after inoculation.
RESULTS: The thickness of gastric pits, COX-2 mRNA and protein levels, and PGE2 levels were significantly increased at 24 weeks after inoculation of H. pylori compared with the control groups. Treatment with etodolac resulted in significant decreases in PGE2 production and in the thickness of gastric pits in the infected groups at 24 weeks after inoculation.
CONCLUSIONS: Our findings suggest that COX-2 is involved in the development of hyperplastic gastritis caused by H. pylori infection via the production of PGE2.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11380326     DOI: 10.1046/j.1365-2036.2001.00965.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  6 in total

Review 1.  Role of cyclooxygenase-2 in gastric cancer development and progression.

Authors:  Jian Cheng; Xiao-Ming Fan
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

Review 2.  Non-steroidal anti-inflammatory drugs in prevention of gastric cancer.

Authors:  Yun Dai; Wei-Hong Wang
Journal:  World J Gastroenterol       Date:  2006-05-14       Impact factor: 5.742

3.  A New Pharmacokinetic Model Describing the Biodistribution of Intravenously and Intratumorally Administered Superparamagnetic Iron Oxide Nanoparticles (SPIONs) in a GL261 Xenograft Glioblastoma Model.

Authors:  Alexander P Klapproth; Maxim Shevtsov; Stefan Stangl; Wei Bo Li; Gabriele Multhoff
Journal:  Int J Nanomedicine       Date:  2020-06-30

4.  Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice.

Authors:  Hiroko Oshima; Masanobu Oshima; Kayo Inaba; Makoto M Taketo
Journal:  EMBO J       Date:  2004-03-11       Impact factor: 11.598

5.  Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions.

Authors:  Li-Jing Zhang; Shi-Yan Wang; Xiao-Hui Huo; Zhen-Long Zhu; Jian-Kun Chu; Jin-Cheng Ma; Dong-Sheng Cui; Ping Gu; Zeng-Ren Zhao; Ming-Wei Wang; Jun Yu
Journal:  World J Gastroenterol       Date:  2009-06-14       Impact factor: 5.742

6.  Mouse models of gastric cancer.

Authors:  Yoku Hayakawa; James G Fox; Tamas Gonda; Daniel L Worthley; Sureshkumar Muthupalani; Timothy C Wang
Journal:  Cancers (Basel)       Date:  2013-01-24       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.